Pharvaris (PHVS) Projected to Post Earnings on Wednesday

Key Points

• Pharvaris is expected to report Q3 2026 results before the market opens November 11, with analysts forecasting a loss of $0.82 per share and revenue of $2.35 million. The earnings call is scheduled for November 12.
• Analysts give the stock a “Moderate Buy” consensus and an average price target of $59.53; shares recently traded at $34.01. The company’s previous quarter loss of $0.81 per share was wider than the $0.75 consensus estimate.
• Company insiders sold 513,102 shares worth about $18.6 million over the past 90 days, including sales by President Peng Lu and insider Anne Lesage.

Pharvaris (NASDAQ:PHVS - Get Free Report) is projected to post its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Pharvaris to post earnings of ($0.8187) per share and revenue of $2.35 million for the quarter. Individuals may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 12:30 PM ET.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). On average, analysts expect Pharvaris to post ($3.12) EPS for the current fiscal year and ($3.01) EPS for the next fiscal year.

Pharvaris Trading Down 2.2%

Pharvaris stock traded down $0.77 during trading hours on Wednesday, reaching $34.01. 29,833 shares of the stock were exchanged, compared to its average volume of 448,997. The stock has a 50 day moving average of $33.56 and a two-hundred day moving average of $31.04. Pharvaris has a twelve month low of $21.02 and a twelve month high of $43.25. The company has a market cap of $2.22 billion, a P/E ratio of -11.23 and a beta of -2.48.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PHVS. HSBC raised Pharvaris to an "overweight" rating in a research note on Thursday, August 13th. New Street Research set a $60.00 price target on Pharvaris in a research report on Friday, August 14th. Citigroup reissued a "market outperform" rating on shares of Pharvaris in a report on Wednesday, September 9th. Wells Fargo & Company upped their price objective on shares of Pharvaris from $55.00 to $65.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 9th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 target price on shares of Pharvaris in a research report on Monday, September 14th. Fourteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $59.53.

Insider Buying and Selling

In other Pharvaris news, President Peng Lu sold 100,000 shares of the company's stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $35.00, for a total value of $3,500,000.00. Following the completion of the sale, the president owned 64,953 shares in the company, valued at $2,273,355. This represents a 60.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Anne Lesage sold 30,000 shares of Pharvaris stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $38.30, for a total transaction of $1,149,000.00. Following the sale, the insider owned 56,450 shares in the company, valued at approximately $2,162,035. The trade was a 34.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 513,102 shares of company stock worth $18,643,666 over the last 90 days.

Pharvaris Company Profile

Pharvaris N.V. NASDAQ: PHVS is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder that causes recurrent episodes of swelling. The company was founded in 2015 by individuals with experience in HAE drug development and aims to provide convenient, non-injectable treatment options for patients.

Pharvaris' lead investigational product is deucrictibant, an oral bradykinin B2 receptor antagonist designed for use both as an on-demand treatment for HAE attacks and as a preventive therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.